Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting earnings tomorrow after market close. Here’s what to look for.

Supernus Pharmaceuticals beat analysts’ revenue expectations by 12.2% last quarter, reporting revenues of $174.2 million, up 6% year on year. It was a very strong quarter for the company, with an impressive beat of analysts’ EPS estimates and full-year operating income guidance topping analysts’ expectations.

Is Supernus Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Supernus Pharmaceuticals’s revenue to grow 3% year on year to $147.9 million, a reversal from the 6.6% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.37 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Supernus Pharmaceuticals has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 10.4% on average.

Looking at Supernus Pharmaceuticals’s peers in the branded pharmaceuticals segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Bristol-Myers Squibb’s revenues decreased 5.6% year on year, beating analysts’ expectations by 3.9%, and Organon reported a revenue decline of 6.7%, topping estimates by 0.6%. Bristol-Myers Squibb traded down 1.3% following the results while Organon was also down 25.8%.

Read our full analysis of Bristol-Myers Squibb’s results here and Organon’s results here.

There has been positive sentiment among investors in the branded pharmaceuticals segment, with share prices up 4.9% on average over the last month. Supernus Pharmaceuticals is up 1.8% during the same time and is heading into earnings with an average analyst price target of $38.80 (compared to the current share price of $32.84).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.